ARCHIVES

Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week.

This article is from The Cancer Letter archive.

Vol. 30 No. 20 | May 14, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Approve Continuation Of Cancer Genome Atlas Network.

December 19, 2008

Biotech Firm Plans Custom Clinical trials In USSR for Drug Firms

August 18, 1989

In Brief: Senate Subcommittee Adds $100 Million For NCI Over House Bill, No Further Action Until Sept.

August 8, 1975

In Brief: Muggia Leaving NCI For NYU In September; Seminar Planned On radiation Exposures

April 20, 1979

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

NCI-Approved Clinical Trials Listed For May 2001

June 29, 2001